We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Conagra Brands, Inc. (CAG - Free Report) was a big mover last session, as the company saw its shares rise nearly 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $22.37 to $23.38 in the past one-month time frame.
The move came after the company reported better-than-expected third-quarter fiscal 2019 earnings.
The company has seen two positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Conagra Brands. So, make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Conagra Brands currently has a Zacks Rank #4 (Sell) while its Earnings ESP is positive.
Is CAG going up? Or down? Predict to see what others think: Up or Down
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Conagra Brands (CAG) Surges: Stock Moves 12.8% Higher
Conagra Brands, Inc. (CAG - Free Report) was a big mover last session, as the company saw its shares rise nearly 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $22.37 to $23.38 in the past one-month time frame.
The move came after the company reported better-than-expected third-quarter fiscal 2019 earnings.
The company has seen two positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Conagra Brands. So, make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Conagra Brands currently has a Zacks Rank #4 (Sell) while its Earnings ESP is positive.
Conagra Brands Inc. Price
Conagra Brands Inc. Price | Conagra Brands Inc. Quote
A better-ranked stock in the Food – Miscellaneous industry is Associated British Foods PLC (ASBFY - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is CAG going up? Or down? Predict to see what others think: Up or Down
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>